Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy-Reference-Cited by-同舟云学术

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Published:2023-12-22 Issue: Volume: Page:1-4
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Harrysson Sara¹²^ORCID,Eloranta Sandra¹,Ekberg Sara¹,Enblad Gunilla³,Andersson Per-Ola⁴,Sonnevi Kristina²,Ljungqvist Maria¹²,Sander Birgitta⁵,Jerkeman Mats⁶,Smedby Karin E.¹²

Affiliation:

1. Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

2. Department of Hematology, Karolinska University Hospital, Solna, Sweden

3. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

4. Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, and Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

5. Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

6. Department of Oncology, Lund University, Lund, Sweden

Funder

Swedish Cancer Society

Karolinska Institutet and Janssen Pharmaceutica NV

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2296361

Reference15 articles.

1. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

2. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial

3. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma

4. MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial